Novartis: Novartis to present new data from studies across neuroscience portfolio, including 7year disability outcomes and safety analysis of Kesimpta in people with RMS at AAN 2025
Novartis will present data from studies across its neuroscience portfolio, including seven─year disability outcomes and safety data from the ALITHIOS open─label extension trial of Kesimpta (ofatumumab) in
Read full article »
Novartis is a Switzerland-based multinational medicines company that researches and develops generic and pharmaceutical products for the healthcare industry.
Read more